Funding News
August 1, 1999
Funding News
In the last issue, we described some of the programs available through The Cancer Research Institute (CRI, website: www.cancerresearch.org.). In this issue, we continue with CRI’s initiatives in funding research on AIDS, breast cancer, and other malignancies.
Under its Designated Grants Program, CRI supports research projects on various diseases and therapeutic strategies. Designated grants are awarded in the following categories:
The Jane Coffin Childs Memorial Fund provides support in the form of fellowships to young postdoctoral scientists conducting research into the causes, origins, and treatment of cancer. Fellowships are awarded for three years and carry a basic annual stipend of $25,000 in the first year, $26,000 in the second, and $27,000 in the third year, with an additional $750 available for each dependent child. An allowance of $1,500 a year is usually made available to the sponsoring laboratory for the Fellow’s research expenses. Candidates in general should not have more than one year of postdoctoral experience. They must hold either the MD or PhD degree in the field in which they propose to study or furnish evidence of equivalent training and experience. American citizens may hold a fellowship either in the United States or in a foreign country, but foreign nationals will be awarded fellowships only for study in the United States. The annual deadline for receipt of applications is February 1.
The Rhea (Rose Marie) Finnell Memorial Research Fellowship and Breast Cancer Care Program. The Finnell family established this program in 1995 to raise funds in memory of Rhea Finnell. The program dedicates 75% of funds raised to the CRI for the support of postdoctoral fellows investigating how to mobilize the immune system against breast cancer. Twenty-five percent of funds go to programs at the Strang Cornell Breast Center to provide immediate patient care for those suffering from breast cancer.
AIDS Program. CRI provides funding to scientists investigating how the AIDS virus infects the cells of the human immune system and how the virus can be deterred. CRI’s commitment to AIDS research dates to 1983. CRI was among the first private research funding organizations to recognize the urgency of the emerging AIDS epidemic and to see the relationship of the disease to certain types of cancer.
In 1994, CRI established the Systemic Hyperthermia Oncological Working Group (SHOWG), an international cooperative group of clinical investigators whose goal is to define the role of whole-body hyperthermia (WBH) as an adjunct therapy for cancer.
The Institute’s Russia Program was established in 1989 to give Russian scientists the chance to study at premiere laboratories here in the United States. Through the generous support of the Samuel Freeman Charitable Trust and the Oliver S. and Jennie R. Donaldson Charitable Trust, the Russia Program has evolved and now includes support to laboratories in the United States and Russia.
CRI also supports the International Symposia Series, a series of annual meetings focusing on progress in cancer vaccine research and antibody-based therapies. In addition to the CRI-Concern Foundation and the Gar Reichman Programs, which support ongoing research in established laboratories, CRI also underwrites the William B. Coley Award for Distinguished Research in Immunology and the Oliver R. Grace Award for Distinguished Service in Advancing Cancer.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content